Strategic Regulatory Evaluation and Endorsement of the Hollow Fiber Tuberculosis System as a Novel Drug Development Tool.

about

Translating the Tuberculosis Research Agenda: Much Accomplished, but Much More to Be Done.Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease.The Role of Public-Private Partnerships in Catalyzing the Critical Path.

P2860

Q36094210-99385F2E-B5B4-4389-95B3-026F6BD3AE41 Q36933441-ED9C2D5D-04D2-416F-BF15-819702F389AB Q53707802-2C35873F-570B-42AF-A581-2CC1985E9529

P2860

Strategic Regulatory Evaluation and Endorsement of the Hollow Fiber Tuberculosis System as a Novel Drug Development Tool.

Item

http://www.wikidata.org/entity/Q38557282

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Strategic Regulatory Evaluatio ...... a Novel Drug Development Tool.

@en

type

Item

label

Strategic Regulatory Evaluatio ...... a Novel Drug Development Tool.

@en

prefLabel

Strategic Regulatory Evaluatio ...... a Novel Drug Development Tool.

@en

P1476

Strategic Regulatory Evaluatio ...... a Novel Drug Development Tool.

@en

P2093

Debra Hanna

http://www.w3.org/2001/XMLSchema#string

Klaus Romero

http://www.w3.org/2001/XMLSchema#string

Robert Clay

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.

Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.

Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.

The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model.

Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.

P304

S5-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIV424

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

61 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280584845

http://www.w3.org/2001/XMLSchema#string

P698

26224771

http://www.w3.org/2001/XMLSchema#string

Strategic Regulatory Evaluation and Endorsement of the Hollow Fiber Tuberculosis System as a Novel Drug Development Tool.

about

P2860

P2860

Strategic Regulatory Evaluation and Endorsement of the Hollow Fiber Tuberculosis System as a Novel Drug Development Tool.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P5875

P698